Table 3.
Drugs associated with PD-L1 regulation
| Drug | Target | Cancer type | Model type |
|---|---|---|---|
| Stri-201 | STAT3-PD-L1 | ↓HNSCC[130] | mouse |
|
Nexturastat Tubastatin A |
HDAC6-STAT3-PD-L1 | ↓melanoma[131] | cell |
| Silvestrol | EIF4F-STAT1-PD-L1 | ↑melanoma[132] | mouse |
| Verteporfin | STAT1-IRF1-TRIM28 | ↓multiple cancers[133] | cell |
| Verticillin A | MLL1- H3K4me3 | ↓PC[134] | cell |
| Cisplatin | miR-145- c-MYC-PD-L1 | ↑ovarian carcinoma[135] | cell |
| PROTACs | PD-L1 ubiquitination and lysosomal degradation | ↓multiple cancers[138, 139] | mouse |
| PD-LYSO | HIP1R-PD-L1 | ↓multiple cancers[140] | cell |
| Crcumin | CSN5-PD-L1 | ↓BC[97] | mouse |
| Decitabine | DNA hypomethylation | ↑CC, leukemia, HNSCC, NSCLC [60, 142–144] | mouse |
| Temozolomide | STAT3-PD-L1 | ↑glioblastoma multiforme[145] | mouse |
| Regorafenib |
RET-Src-JAK1/2-STAT1; RET-Src- MAPK signaling |
↑melanoma[146] | mouse |
| Mifepristone | glucocorticoid receptor-PD-L1 | ↓PC[147] | mouse |
| Metformin | PD-L1 glycosylation | ↓breast tumor, melanoma, and colon cancer[109, 148] | mouse |
| Capmatinib | MET-PD-L1 | ↓PC[149] | mouse |
| Albendazole | PD-L1 ubiquitination | ↓melanoma[101] | mouse |
The up and down arrows represent the up- and down-regulation of PD-L1, respectively.